-
Loading metrics
Open Access
Peer-reviewed
Research Article
Inhibition of HER2 signaling and breast cancer cell growth with a novel antibody targeting HER2 ECD III/IV
-
Chunchun Liu ,
Contributed equally to this work with: Chunchun Liu, Yulei Ren, Xuan Luo
Roles Investigation, Methodology, Writing – original draft
* E-mail: liuchun880616@yeah.net (CL); danzhao5278@foxmail.com (DZ); yanghr@fudan.edu.cn (HY)
Affiliation Fudan University Shanghai Cancer Center, Institutes of Biomedical Sciences, Shanghai Key Laboratory of Radiation Oncology, and Shanghai Key Laboratory of Medical Epigenetics, Shanghai Medical College of Fudan University, Shanghai, China
⨯ -
Yulei Ren ,
Contributed equally to this work with: Chunchun Liu, Yulei Ren, Xuan Luo
Roles Software, Visualization
Affiliation Fudan University Shanghai Cancer Center, Institutes of Biomedical Sciences, Shanghai Key Laboratory of Radiation Oncology, and Shanghai Key Laboratory of Medical Epigenetics, Shanghai Medical College of Fudan University, Shanghai, China
⨯ -
Xuan Luo ,
Contributed equally to this work with: Chunchun Liu, Yulei Ren, Xuan Luo
Roles Methodology
Affiliations Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
⨯ -
Peiyun Zhou,
Roles Methodology
Affiliation Fudan University Shanghai Cancer Center, Institutes of Biomedical Sciences, Shanghai Key Laboratory of Radiation Oncology, and Shanghai Key Laboratory of Medical Epigenetics, Shanghai Medical College of Fudan University, Shanghai, China
⨯ -
Xiangjuan Du,
Roles Methodology
Affiliation Fudan University Shanghai Cancer Center, Institutes of Biomedical Sciences, Shanghai Key Laboratory of Radiation Oncology, and Shanghai Key Laboratory of Medical Epigenetics, Shanghai Medical College of Fudan University, Shanghai, China
⨯ -
Qianmin Wang,
Roles Software, Visualization
Affiliation Fudan University Shanghai Cancer Center, Institutes of Biomedical Sciences, Shanghai Key Laboratory of Radiation Oncology, and Shanghai Key Laboratory of Medical Epigenetics, Shanghai Medical College of Fudan University, Shanghai, China
⨯ -
Xue Han,
Roles Methodology, Software
Affiliation Fudan University Shanghai Cancer Center, Institutes of Biomedical Sciences, Shanghai Key Laboratory of Radiation Oncology, and Shanghai Key Laboratory of Medical Epigenetics, Shanghai Medical College of Fudan University, Shanghai, China
⨯ -
Yanhui Xu,
Roles Project administration, Supervision
Affiliations Fudan University Shanghai Cancer Center, Institutes of Biomedical Sciences, Shanghai Key Laboratory of Radiation Oncology, and Shanghai Key Laboratory of Medical Epigenetics, Shanghai Medical College of Fudan University, Shanghai, China, The International Co-laboratory of Medical Epigenetics and Metabolism, Ministry of Science and Technology, Shanghai, China, Department of Systems Biology for Medicine, School of Basic Medical Sciences, Shanghai Medical College of Fudan University, Shanghai, China
⨯ -
Ping Wang,
Roles Methodology
Affiliation Molinsights Biotechnologies, Guangdong Medical Valley Life Science Park, Guangzhou, China,
⨯ -
Dan Zhao ,
Roles Methodology, Project administration
* E-mail: liuchun880616@yeah.net (CL); danzhao5278@foxmail.com (DZ); yanghr@fudan.edu.cn (HY)
Affiliations Fudan University Shanghai Cancer Center, Institutes of Biomedical Sciences, Shanghai Key Laboratory of Radiation Oncology, and Shanghai Key Laboratory of Medical Epigenetics, Shanghai Medical College of Fudan University, Shanghai, China, School of Life Sciences, Greater Bay Area Institute of Precision Medicine (Guangzhou), Fudan University, Guangzhou, China
⨯ -
Huirong Yang
Roles Project administration, Supervision, Writing – review & editing
* E-mail: liuchun880616@yeah.net (CL); danzhao5278@foxmail.com (DZ); yanghr@fudan.edu.cn (HY)
Affiliations Fudan University Shanghai Cancer Center, Institutes of Biomedical Sciences, Shanghai Key Laboratory of Radiation Oncology, and Shanghai Key Laboratory of Medical Epigenetics, Shanghai Medical College of Fudan University, Shanghai, China, The International Co-laboratory of Medical Epigenetics and Metabolism, Ministry of Science and Technology, Shanghai, China, Department of Systems Biology for Medicine, School of Basic Medical Sciences, Shanghai Medical College of Fudan University, Shanghai, China
⨯
Inhibition of HER2 signaling and breast cancer cell growth with a novel antibody targeting HER2 ECD III/IV
- Chunchun Liu,
- Yulei Ren,
- Xuan Luo,
- Peiyun Zhou,
- Xiangjuan Du,
- Qianmin Wang,
- Xue Han,
- Yanhui Xu,
- Ping Wang,
- Dan Zhao
- Published: January 15, 2026
- https://doi.org/10.1371/journal.pone.0338127